ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

florensocatib

Also written as “HSK31858, tablet”, “HSK31858” and “HSK31858 tablets”.

Its studies are mostly in Bronchiectasis · Asthma, led by 2 companies.

Drug pageFlorensocatib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 202416 company-led studies, 13 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Groupits history only1310 open or runningphase 3since Sep 23, 2024Aug 16, 2021Nov 2026phase 1 · NCT07915024
Chiesi Farmaceuticiits history only33 open or runningphase 3since Apr 27, 2026Apr 27, 2026Dec 9, 2026phase 1 · NCT07683793

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2021First study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT05023525 · 32 enrolled · Australia
  2. Oct 27, 2022Phase 2 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)Haisco Pharmaceutical Group · NCT05601778 · 226 enrolled · China
  3. Dec 6, 2022Phase 1 study in Healthy VolunteersHaisco Pharmaceutical Group · NCT05663593 · 74 enrolled · China
  4. Aug 19, 2024Phase 1 study in HealthyHaisco Pharmaceutical Group · NCT06569784 · 6 enrolled · China
  5. Sep 23, 2024Phase 3 study in Non-cystic Fibrosis BronchiectasisHaisco Pharmaceutical Group · NCT06660992 · 669 planned · China
  6. Oct 9, 2024Phase 2 study in AsthmaHaisco Pharmaceutical Group · NCT06637254 · 219 planned · China
  7. Feb 6, 2025Phase 2 study in BronchiectasisHaisco Pharmaceutical Group · NCT06820749 · 309 planned · China
  8. Feb 13, 2025Named florensocatibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, HSK31858, CHF10196
  9. Aug 14, 20252 phase 1 studies in Healthy SubjectsHaisco Pharmaceutical Group · NCT07134478, NCT07134465
  10. Apr 27, 2026Chiesi Farmaceutici’s first study: phase 3 study in BronchiectasisNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT07577804 · 904 planned
  11. May 23, 2026Phase 3 study in Non-cystic Fibrosis BronchiectasisHaisco Pharmaceutical Group · NCT07616375 · 669 planned · China
  12. Jun 26, 2026Phase 1 study in Healthy VolunteersChiesi Farmaceutici · NCT07683793 · 18 planned · United Kingdom
  13. Jul 23, 2026Phase 1 study in Healthy Male VolunteersChiesi Farmaceutici · NCT07744386 · 24 planned · United Kingdom
  14. Oct 28, 20263 phase 1 studies in Non-cystic Fibrosis Bronchiectasis (NCFBE)Haisco Pharmaceutical Group · NCT07913009, NCT07915024, NCT07915011

Ahead

  1. Nov 2026Primary completion: phase 1 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)Haisco Pharmaceutical Group · NCT07915024
  2. Nov 2026Primary completion: phase 1 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)Haisco Pharmaceutical Group · NCT07915011
  3. Nov 28, 2026Primary completion: phase 3 study in Non-cystic Fibrosis BronchiectasisHaisco Pharmaceutical Group · NCT06660992
  4. Nov 30, 2026Primary completion: phase 1 study in Healthy SubjectsHaisco Pharmaceutical Group · NCT07134465

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07915024Non-cystic Fibrosis Bronchiectasis (NCFBE) · China1RecruitingHaisco Pharmaceutical GroupNov 202647
NCT07915011Non-cystic Fibrosis Bronchiectasis (NCFBE) · China1RecruitingHaisco Pharmaceutical GroupNov 202624
NCT07913009Non-cystic Fibrosis Bronchiectasis (NCFBE) · China1RecruitingHaisco Pharmaceutical GroupDec 202630
NCT07744386Healthy Male Volunteers · United Kingdom1Not yet recruitingChiesi FarmaceuticiDec 15, 202824
NCT07683793Healthy Volunteers · United Kingdom1Not yet recruitingChiesi FarmaceuticiDec 9, 202618
NCT07616375Non-cystic Fibrosis Bronchiectasis · China3RecruitingHaisco Pharmaceutical GroupJan 10, 2029669
NCT07577804Bronchiectasis3Not yet recruitingChiesi FarmaceuticiApr 2030904
NCT07134478Healthy Subjects · China1Active, not recruitingHaisco Pharmaceutical GroupDec 24, 202424
NCT07134465Healthy Subjects · China1By invitationHaisco Pharmaceutical GroupNov 30, 202624
NCT06820749Bronchiectasis · China2By invitationHaisco Pharmaceutical GroupApr 23, 2026309
NCT06637254Asthma · China2By invitationHaisco Pharmaceutical GroupMar 22, 2026219
NCT06660992Non-cystic Fibrosis Bronchiectasis · China3RecruitingHaisco Pharmaceutical GroupNov 28, 2026669
NCT06569784Healthy · China1Active, not recruitingHaisco Pharmaceutical GroupJul 2, 20246
NCT05663593Healthy Volunteers · China1CompletedHaisco Pharmaceutical GroupAug 15, 202274
NCT05601778Non-cystic Fibrosis Bronchiectasis (NCFBE) · China2CompletedHaisco Pharmaceutical GroupMar 29, 2024226
NCT05023525Healthy · Australia1CompletedHaisco Pharmaceutical GroupApr 19, 202232

How it is read

Names in the registry

  • “HSK31858, tablet”, 4 entries
  • “HSK31858”, 3 entries
  • “HSK31858 tablets”, 2 entries
  • “CHF10196”, 2 entries
  • “HSK31858 tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.